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Abstract Mitoxantrone (MTX) is an antitumor agent that
causes cardiotoxicity in 18 % patients. The metabolic
profile of MTX was assessed after incubation of 100 lM
MTX with hepatic S9 fraction isolated from rats. The
presence of MTX and its metabolites was also assessed
in vivo through the analysis of liver and heart extracts of
MTX-treated rats. The cytotoxic effects of MTX and MTX
metabolites were evaluated in the H9c2 cells after 24-h
incubation with MTX alone and MTX ? metabolites. The
influence of CYP450- and CYP2E1-mediated metabolism
for the cytotoxicity of MTX was assessed after 96-h
incubation with MTX (100 nM and 1 lM) in the presence/
absence of CYP450 or CYP2E1 inhibitors. After 4-h
incubation in supplemented S9 fraction, the MTX content
was 35 % lower and 5 metabolites were identified: an
acetoxy ester derivative (never described before), two
glutathione conjugates, a monocarboxylic acid derivative,
and the naphtoquinoxaline, the later commonly related to
MTX pharmacological effects. The presence of MTX and
naphtoquinoxaline metabolite was evidenced in vivo in
liver and heart of MTX-treated rats. The cytotoxicity
caused by MTX ? metabolites was higher than that
observed in the H9c2 cells incubated with non-metabolized
MTX group. The co-incubation of MTX with CYP450 and
CYP2E1 inhibitors partially prevented the cytotoxicity
observed in the MTX groups incubated with H9c2 cells,
highlighting that the metabolism of MTX is relevant for its
undesirable effects. The naphtoquinoxaline metabolite is
described in heart and liver in vivo, highlighting that this
metabolite accumulates in these tissues. It was demon-
strated that MTX P450-mediated metabolism contributed
to MTX toxicity.
Keywords Mitoxantrone  Metabolism  Bioactivation 
LC/MS  S9 fraction  Cardiotoxicity
Abbreviations
DAD Photodiode array
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MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide
MTP Metyrapone
MTX Mitoxantrone
b-NADPH b-Nicotinamide adenine dinucleotide
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Introduction
Mitoxantrone (MTX) is an anticancer drug synthesized in
the end of 1970s as an alternative to anthracyclines therapy
(Canal et al. 1993). It has been largely used in the treatment
of solid tumors, acute leukemia, lymphoma, prostate, and
breast cancer (Seiter 2005) and, more recently, in the active
forms of relapsing–remitting or secondary progressive
multiple sclerosis (Neuhaus et al. 2006). Despite its broad
utilization, MTX is potentially cardiotoxic (Seiter 2005;
Avasarala et al. 2003).
The pharmacological activity of MTX is based on the
ability to intercalate its planar electron-rich chromophore
group in the DNA and to allow electrostatic interactions of
its side chains with the phosphate moiety of DNA (Ehn-
inger et al. 1990). Furthermore, MTX causes single and
double breaks in DNA by stabilization of a complex
formed between DNA and topoisomerase II (Ehninger
et al. 1990; Seiter 2005). As a consequence, MTX inhibits
DNA replication, RNA transcription, and also affects the
cell cycle at various stages (Khan et al. 2010; Ehninger
et al. 1990).
The oxidoreductive metabolism of MTX has a signifi-
cant role on its antitumor effects. MTX has particular
effectiveness in tumors with high contents of peroxidases
(Bru¨ck and Bru¨ck 2011; Blanz et al. 1991), and it was
verified that the inhibitory effect of MTX on cell growth
was prevented by inhibiting the activity of cytochrome
P450 mixed oxidase function in a human hepatoma-derived
cell line (Duthie and Grant 1989). Similar results were
obtained with a rat hepatocytes model (Mewes et al. 1993)
and with human breast cancer cells (Li et al. 1995). Phorbol
ester-stimulated human neutrophils can bioactive MTX
through myeloperoxidase metabolism, and the generated
metabolites can form adducts with DNA (Panousis et al.
1997). Furthermore, it was already demonstrated that a
synthetic cyclic metabolite of MTX, the 8,11-dihydroxy-4-
(2-hydroxyethyl)-6-[[2-[(2-hydroxyethyl)amino]ethyl]
amino]-1,2,3,4,7,12-hexahydronaphto-[2-3]-quinoxaline-7-
12-dione or naphtoquinoxaline metabolite, causes cellular
damage in neonatal cardiomyocytes isolated from rats
(Shipp et al. 1993). This metabolite was already described
as an in vivo MTX biotransformation product in humans,
pigs, and rats (Blanz et al. 1991). With the exception of the
study mentioned above (Shipp et al. 1993), to the best of
our knowledge, there are no studies relating the bioprod-
ucts of MTX with its most serious undesirable effect: the
late irreversible cardiotoxicity (Avasarala et al. 2003).
Pharmacokinetic studies showed that after intravenous
administration, MTX has a rapid distribution followed by a
slow elimination phase characterized by an extensive
accumulation in highly perfused organs in humans and
laboratory animals (Ehninger et al. 1990; Batra et al. 1986).
The metabolism of MTX involves the oxidation through
the microsomal system and/or peroxidase enzymes such as
neutrophil myeloperoxidase (Duthie and Grant 1989;
Panousis et al. 1997). Moreover, the phase II metabolism
has a relevant role in the MTX detoxification process,
namely the conjugation with reduced glutathione (GSH)
and glucuronic acid (Ehninger et al. 1990). Considering the
interspecies variability, the main metabolic difference
between rats and humans is that mono and dicarboxylic
acid derivatives of MTX are major bioproducts of human
metabolism, while in rats, they are residual (Blanz et al.
1991; Richard et al. 1991).
The difficulty to reproduce the oxidoreductive metabo-
lism of MTX in in vitro conditions is extensively reported
(Wolf et al. 1986; Richard et al. 1991; Basra et al. 1985;
Kostrzewa-Nowak et al. 2007; Fisher and Patterson 1992;
Fisher et al. 1993). Because of that, some authors use
exogenously added isolated enzymes such as NADPH
cytochrome P450 reductase (Kostrzewa-Nowak et al. 2007;
Novak and Kharasch 1985) and peroxidase enzymes sys-
tem (Blanz et al. 1991; Bru¨ck and Bru¨ck 2011) in order to
circumvent this limitation. Nevertheless, from all in vitro
methods, these are the less realistic ones. There are also
metabolic studies employing more representative systems,
namely using primary cultures of hepatocytes isolated from
rats, rabbits, and humans (Richard et al. 1991), micro-
somes, and cytosol fractions isolated from rat livers (Wolf
et al. 1986). The referred studies use HPLC/UV methods to
detect and quantify the metabolites (Richard et al. 1991;
Wolf et al. 1986), which limit the analysis due to the low
sensitivity of UV detector and do not allow the structural
elucidation of the metabolites. Alternative methods use
liquid scintillation counting equipped with a radioactive
flow detector (Richard et al. 1991), which is not commonly
available in the majority of analytical laboratories and
requires the undesirable use of labeled compounds.
We present herein a study that aims to assess the con-
tribution of MTX metabolism to its cardiotoxicity. The
metabolic profile of MTX was studied using the hepatic S9
fraction from phenobarbital-induced animals, which are
considered a representative hepatic model for this purpose
as it contains both phase I and II enzymes involved in the
MTX metabolism (Brandon et al. 2003; Jia and Liu 2007).
The MTX metabolites were separated by liquid chroma-
tography (LC) coupled with a UV–VIS photodiode array
detector (DAD) and accurately identified by electrospray
ionization interface (ESI) mass spectrometry detector (MS)
that possess a higher sensitivity and accuracy. The cyto-
toxic effects of MTX metabolites and the influence of
CYP450 and CYP2E1 metabolism in the cytotoxicity of
MTX were evaluated in the H9c2 cells, a valuable car-
diomyoblast in vitro model (Zordoky and El-Kadi 2007).
An in vivo study was also performed in order to investigate
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whether the MTX metabolites previously found in vitro
were also present in the liver and heart of rats after MTX
intraperitoneal administration.
Materials and methods
Chemicals
All chemicals and reagents were of analytical grade. MTX
hydrochloride, GSH, reduced b-nicotinamide adenine
dinucleotide phosphate (b-NADPH), metyrapone (MTP),
diallyl sulfide (DAS), and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were obtained from
Sigma-Aldrich (St. Louis, MO, USA). Methanol, dimethyl
sulfoxide (DMSO), and formic acid were obtained from
Merck (Darmstadt, Germany).
Dulbecco’s modified eagle’s medium (DMEM) with
4,500 mg/L glucose and GlutMAXTM, fetal bovine serum
FBS, trypsin (0.25 %)—EDTA (1 mM), and antibiotic
(10,000 U/mL penicillin, 10,000 g/mL streptomycin) were
obtained from Gibco Laboratories (Lenexa, KS, USA).
Animals
Adult male Wistar rats (Charles River Laboratories, Bar-
celona, Spain) weighing 300–350 g were used. The ani-
mals were acclimated, housed in cages, with a
temperature- and humidity-controlled environment. Food
and water were provided ad libitum, and animals were
subjected to a 12-h light–dark cycle. Animal experiments
were licensed by Portuguese General Directory of Veter-
inary Medicine. Housing and experimental treatment of
the animals were in accordance with the Guide for the
Care and Use of Laboratory Animals from the Institute for
Laboratory Research. The experiments complied with
current Portuguese laws.
Isolation of the hepatic S9 fraction
The animals used for the hepatic S9 fraction isolation
received phenobarbital 0.2 % in drinking water for 1 week
prior to the excision of the livers, in order to induce
metabolism (Wolf et al. 1986). All the animals were
monitored, and no signals of toxicity were observed.
The animals were killed through cervical dislocation.
The livers were excised, washed with 100 mM phosphate
buffer, pH 7.4 (in order to remove the excess of blood),
dried, and weighed. Livers were homogenized in 100 mM
phosphate buffer, pH 7.4 (1 g/4 mL of buffer), and cen-
trifuged 9,0009g, 20 min, 4 C. The supernatant contains
the S9 fraction. All steps were carefully performed on ice.
An aliquot was used to quantify the protein levels by
Lowry method (Rossato et al. 2011, Lowry et al. 1951).
Evaluation of the metabolic profile of MTX
Prior to the incubations, the protein density of the S9 fraction
was adjusted to contain 4 mg/mL in 100 mM phosphate
buffer, pH 7.4 (Wolf et al. 1986). Samples were supple-
mented with 1 mM NADPH and 4 mM GSH, as previously
reported (Wolf et al. 1986). The incubations were carried out
using 100 lM MTX, at 37 C, for 4-h. Aliquots of this mix
were taken at the incubation times 0 and 4-h. One blank tube
containing control supplemented S9 fraction (without MTX)
was also incubated and further analyzed in order to evaluate
possible matrix interferences. One tube containing only
100 lM MTX ? 1 mM NADPH ? 4 mM GSH (without
the S9 fraction) was also evaluated in order to rule out the
possibility of artifacts formation.
At 0 and 4-h, methanol was added to the samples (ratio
of 1:4 methanol) in order to precipitate the proteins and to
extract MTX and the metabolites. Samples were centri-
fuged at 16,0009g, 5 min, 4 C, and the supernatant was
dried under nitrogen flux. The residues were re-suspended
in 200 lL of methanol and analyzed by LC/DAD-ESI/MS
or in 100 lL phosphate saline buffer for the assessment of
cytotoxicity (in detail addressed below).
The incubations with S9 fraction were independently
performed in 3 different days with S9 fraction isolated
from 3 different animals.
In vivo metabolic study
A study using male Wistar rats was performed in order to
verify the presence of MTX metabolites in liver and heart.
Three animals received a single dose of 7.5 mg/kg of
MTX, via intraperitoneal, and were killed 24-h after
treatment. The animals were anesthetized with xilasin/
ketamine (10 mg/kg/100 mg/kg) and were killed after
diaphragm rupture. The livers and hearts were excised and
processed as previously described (An and Morris 2010),
with minors adaptations. Briefly, the organs were homo-
genized with 0.1 M citric buffer containing 100 mg/mL
ascorbic acid, pH 3.0. MTX, and its metabolites were
extracted after the sequential addition of sulfosalicylic acid
(50 lL, final concentration of 5 %) and acetonitrile
(150 lL) to the tissue homogenate (200 lL). Samples were
centrifuged at 16,0009g, 10 min, 4 C, and the superna-
tant was dried under nitrogen flux. The residues were
re-suspended in 200 lL methanol and analyzed by LC/
DAD-ESI/MS, as described below. Control organs (from
animals that did not receive MTX) were also evaluated in
order to assess matrix interferences.
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LC-DAD/ESI–MS analysis
A Finnigan Surveyor series LC, equipped with Lichrocart
Purospher Star reversed-phase column (25 cm 9 4.6 mm
inner diameter, 5 lM, C18), was used. The samples were
analyzed using aqueous 0.5 % (v/v) formic acid as solvent
A and acetonitrile as solvent B (Bru¨ck and Bru¨ck 2011).
The pH of the mobile phase was set to 3.0 with formic acid.
The gradient profile was 90 % (v/v) A/10 % (v/v) B for
1 min and, subsequently, the percentage of acetonitrile was
ramped linearly to 80 % B over a time span of 20 min
(Bru¨ck and Bru¨ck 2011). The analysis was done at a flow
rate of 0.5 mL/min. The sample injection volume was
25 lL. The chromatographic column was stabilized with
the initial conditions for 10 min. Double-online detection
was done by a DAD and MS detectors. The MS detector was
a Finnigan LCQ DECA XP MAX (Finnigan Corp., San
Jose, CA, USA) quadrupole ion trap equipped with atmo-
spheric pressure ionization source, using ESI. The vaporizer
and the capillary voltages were 5 kV and 4 V, respectively.
The capillary temperature was set at 325 C. Nitrogen was
used as both sheath and auxiliary gas at flow rates of 90 and
35, respectively (in arbitrary units). Spectra were recorded
in positive ion mode between m/z 250 and 1,100.
Comparison of the cytotoxic effects of non-metabolized
MTX and MTX metabolites in H9c2 cells
The H9c2 cell line was a generous gift from Dr. Vilma
Sarda˜o, Center for Neurosciences and Cellular Biology,
University of Coimbra, Portugal. Cells were cultured in
DMEM supplemented with 10 % fetal bovine serum,
100 U/mL of penicillin, and 100 U/mL of streptomycin in
75 cm2 tissue culture flasks at 37 C in a humidified
atmosphere of 5 % CO2, 95 % air atmosphere. Cells were
fed every 2–3 days and sub-cultured once they reached
70–80 % confluence (Sarda˜o et al. 2009a, b).
Cells were seeded at a density of 35,000 cells/mL in
48-well plates (final volume of 250 lL; about 8,000 cells/
cm2) and were allowed to grow for 2 days. On the day of
experiment, the medium was replaced and cells were
divided into four groups (six-well per group): (a) control
group (without treatment), (b) matrix group (the previously
4-h incubated S9 liver fraction enriched with 1 mM
NADPH and 4 mM GSH), (c) MTX ? metabolites group
(the product of 4-h incubation of S9 liver fraction ? 1 mM
NADPH ? 4 mM GSH ? 100 lM MTX), and (d) non-
metabolized MTX group (S9 liver fraction ? 1 mM
NADPH ? 4 mM GSH ? 100 lM MTX, on time 0 of
incubation). The presence/absence of metabolites in the
groups (c) and (d), respectively, was confirmed by LC/
DAD-ESI/MS prior to the incubations. The cytotoxic
effects were assessed after 24-h incubation period at 37 C
through the reduction in MTT assay (described in more
detail below). Three independent experiments were per-
formed (with cells seeded on different days and incubated
with samples obtained from S9 fraction isolated from 3
different animals).
Assessment of the protective effect of the co-incubation
of MTX and P450 cytochrome metabolism inhibitors
in H9c2 cells
The CYP450 inhibitor MTP (0.5 mM) (Duthie and Grant
1989; Mewes et al. 1993; Li et al. 1995) and the CYP2E1
subtype inhibitor DAS (150 lM) (Pontes et al. 2010) were
co-incubated with MTX (100 nM and 1 lM) at 37 C for
96-h. MTP was dissolved in DMSO; thus, a group with
only the vehicle (DMSO 0.1 %) was also included. The
potential protective effect of metabolism inhibitors in the
cytotoxicity of MTX was assessed through the MTT assay.
MTT reduction assay
The cytotoxicity upon H9c2 cells was assessed through the
reduction of MTT. At the end of incubation period, the
medium was removed and the cells were washed with
phosphate saline buffer, pH 7.4, followed by the addition of
fresh cell culture medium containing 0.5 mg/L MTT and
incubated at 37 C in a humidified, 5 % CO2, 95 % air
atmosphere for 4-h. After this incubation period, the cell
culture medium was removed and the formed formazan
crystals were dissolved in 100 % DMSO. The absorbance
was measured at 550 nm in a multi-well plate reader
(BioTek Instruments, Vermont, US). The percent of the
MTT reduction relative to control cells was used as the
cytotoxicity measure (Silva et al. 2011).
Statistical analysis
Results are presented as mean ± standard deviation
(n = 18 per condition out of 3 independent studies). Since
the MTT results passed the normality test, a parametric test
was used. One-way ANOVA was performed to compare
means of different groups followed by the Student–New-
man–Keuls post hoc test. Statistical significance was
accepted at p values \0.05.
Results
Metabolic profile of MTX after incubation
with supplemented rat hepatic S9 fraction
It was possible to demonstrate the metabolism of MTX
using hepatic S9 fraction isolated from adult rats
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supplemented with 1 mM NADPH and 4 mM GSH. As
shown in the Fig. 1, the MTX has a retention time of about
15 min. After 4-h incubation of the MTX with the sup-
plemented S9 fraction, a significant decrease of about 35 %
in the MTX peak area was observed, highlighting MTX
metabolism in this in vitro system. Moreover, after 4-h, 5
additional chromatographic peaks were present and were
numerically identified on the LC-DAD/ESI–MS chro-
matogram (Fig. 1). The peaks 1 and 3 were present in small
amounts in time 0, their areas increasing at time 4-h. The
peaks 2, 4 (trace), and 5 were only found after the 4-h
incubation period (Fig. 1). In Fig. 2, the UV–VIS DAD
spectral properties of MTX and its metabolites are pre-
sented, showing that all metabolites identified still possess
the tricyclic planar chromophore group.
Data about the retention times, the MS fragmentation
pattern, and the proposed structure of MTX and its metab-
olites are summarized on Table 1. MTX was unequivocally
identified on the basis of its already described UV–VIS
spectral features (Fig. 2) (Ehninger et al. 1990) and its
parent molecular ion mass ([M ? H]?) at m/z 445 (Bru¨ck
and Bru¨ck 2011). The metabolite 5, the naphtoquinoxaline,
was also already reported (Blanz et al. 1991; Bru¨ck and
Bru¨ck 2011), and it has UV–VIS spectrum with maximum
absorbance at 583 and 634 nm (Fig. 2). Its parent molecular
ion mass ([M ? H]?) is m/z 443. Both MTX and metabolite
5 have the same MS/MS daughter fragmentation derived
from cleavages on the side chain: m/z 358 for MTX
and m/z 356 for metabolite 5 ([M ? H?] - CH2 =
CHNH2CH2CH2OH), and m/z 384 for MTX and m/z 382 for
metabolite 5 ([M ? H?] - NH2CH2CH2OH].
The metabolites 1 and 2 are probably the MTX conju-
gates with one and two molecules of GSH, resulting in the
parent molecular ion mass ([M ? H]?) at m/z 750
(metabolite 1) and ([M ? H]?) at m/z 1,055 (metabolite 2)
(Table 1), the same parent molecular ion previously
described for these metabolites (Blanz et al. 1991).
Regarding metabolite 1, the same pattern of fragmentation
of parent ion 750 was obtained (m/z = 477 and m/z = 621)
(Supplementary data). However, considering the metabo-
lite 2, the fragmentation of the ion at m/z 1,055 results in
fragments (m/z 845 and 775) different from those found in
the study performed by Blanz and co-workers (m/z 926 and
797) (Table 1). Thus, the occurrence of structural rear-
rangements or the insertion of the GSH molecules in other
positions is possible. Metabolite 1 presents maximum
absorbance peaks at 619 and 673 nm, and metabolite 2
presents maximum absorbance peaks at 613 and 661 nm
(Fig. 2). The LC/DAD-ESI/MS analysis does not allow a
conclusion about the site of GSH conjugation. However,
we propose the GSH adduct on the dihydroxybenzene part
of MTX molecule for metabolite 1 based on the previous
work of Mewes and co-workers, which elucidated GSH
conjugates chemical structure through two-dimensional
1H-13C-heteronuclear multiple-bond connectivity NMR
technique (Mewes et al. 1993).
The metabolite 3 presents an UV–VIS spectrum similar
to MTX (Fig. 2). Its mass spectrum (Table 1) showed a
parent molecular ion mass ([M ? H]?) at m/z 503 and MS/
MS fragmentations with m/z 442 ([M ? H]?–NH2CH2
CH2OH) and 416 ([M ? H]
?–CH2=CHNH2CH2CH2OH).
The parent ion suggests that this compound has a
Fig. 1 Overlap of LC/DAD-
ESI/MS chromatograms of time
0- and 4-h incubation of rat
hepatic S9 fraction (4 mg/mL)
with 100 lM MTX ? 1 mM
NADPH ? 4 mM GSH
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CH3COO— group introduced in the original molecule of
MTX (Table 1).
Metabolite 4 was found as a trace (Fig. 1), and it pre-
sents maximum absorbance at 610 and 658 nm (Fig. 2).
Due to the small amount of this compound, the only
information given by the mass spectrum was the parent ion
([M ? H]?) at m/z 455. Based on these data, we proposed
for metabolite 4 the chemical structure presented on
Table 1. A compound with the same molecular ion mass
was previously described and associated with the oxidative
metabolism of MTX (Bru¨ck and Bru¨ck 2011).
The analysis of the blank sample (containing only the
supplemented S9 fraction, without the addition of MTX)
revealed no relevant interferences from the matrix on the
retention times of interest. Similarly, no peaks were
observed at the same retention times in the sample con-
taining only 100 lM MTX ? 1 mM NADPH ? 4 mM
GSH (without the S9 fraction) (data not shown).
Metabolic profile of liver and heart extracts
of MTX-treated male rats
The metabolic profile was determined in vivo through the
evaluation of liver and heart extracts of rats that received
7.5 mg/kg of MTX 24-h before. MTX and its metabolites
were extracted and concentrated as described in the
‘‘Materials and methods’’ section and analyzed through
LC/DAD-ESI/MS. Control liver and heart extracts were
also analyzed in order to determine matrix interferences.
More attention was given in the search and identification of
the metabolite 5 due to its known pharmacological activity
(Bru¨ck and Bru¨ck 2011; Shipp et al. 1993).
In the liver extracts of the animals treated with MTX
(Fig. 3a), it was possible to observe the presence of MTX,
with a retention time of about 15 min, and 7 additional
peaks when compared to control livers (data not shown).
All the compounds identified in the chromatogram as
metabolites of MTX are compounds that absorb radiation
between 500 and 700 nm. At the retention time of
18.16 min, it was identified the metabolite 5 due to its UV–
VIS spectrum characteristics and the MS fragmentation
(data not shown). Further structural identification of the
other metabolites was not possible due to the huge back-
ground presented in the analysis. The metabolites that have
the retention times of 13.21 and 13.70 min possess a UV–
VIS spectrum profile similar to the metabolite 1, with
maximum absorbance in the visible region set at 619 and
673 nm (data not shown). The metabolite with the retention
time of 14.04 min has the same absorbance peaks in the
visible region of the metabolite 4, namely 610 and 658 nm
(data not shown). The metabolites with the retention times
of 14.62, 15.39, and 15.79 min have a UV–VIS spectrum
Fig. 2 UV–VIS spectral data (between 240 and 700 nm) of MTX and
its metabolites after 4-h incubation with rat hepatic S9 fraction
supplemented with 1 mM NADPH ? 4 mM GSH. The metabolites
number designations are in accordance with the chromatogram
showed in Fig. 1
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with absorbance set at 610 and 661 nm, which are the
absorbance maximum peaks of metabolite 3 and MTX.
In heart extracts (Fig. 3b), it was only observed the
presence of MTX (retention time about 15 min) and
metabolite 5 (retention time about 18 min), in trace
amounts. Both compounds were identified through analysis
of their DAD spectrum properties and MS fragmentation.
None of the other peaks were identified as other MTX
metabolites.
The metabolites of MTX increase the toxicity
in a cardiomyoblast in vitro model
The cytotoxicity of MTX and pre-incubated MTX meta-
bolic S9 fraction was assessed in cardiomyoblast model
through the reduction of MTT assay after a time
period incubation of 24-h. The treatment groups result
from the extracts of the previous incubations of the sup-
plemented S9 fraction with 100 lM MTX (with the
exception of the matrix group, which did not contain MTX)
at time 0 (non-metabolized MTX) or 4-h (MTX and its
metabolites). The presence of MTX metabolites after 4-h
incubation with S9 fraction was previously confirmed by
LC/DAD-ESI/MS analysis, highlighting the presence of
peaks of metabolites and a reduction of 35 % of the MTX
content at this time point (Fig. 1). Figure 4 presents the
cytotoxicity results expressed as percent of the MTT
reduction compared to control. As it can be seen, the
incubation with the matrix group (S9 fraction ? 1 mM
NADPH ? 4 mM GSH after 4-h incubation at 37 C) did
not reveal any measurable toxic effect compared to control
(96 ± 2 % vs. 100 ± 1 %, respectively). The MTX group
and the MTX ? metabolites group showed a significantly
decrease in % of MTT reduction compared to control
(79 ± 2 % for the MTX group and 67 ± 2 % for the
MTX ? metabolites group). In the group MTX ? metab-
olites, the cytotoxic effects were significantly more pro-
nounced, even with 35 % less MTX, compared to MTX
group, highlighting that its metabolism increases the
cytotoxicity caused by MTX in the cardiomyoblast model.
Table 1 Proposed chemical structure, retention times, and mass spectrum of MTX and its metabolites obtained through LC-DAD/ESI–MS after
4-h incubation of 100 lM MTX in supplemented S9 fraction
Compound Chemical structure Retention time (LC/MS) (min) MS parent-ion mass [m/z] MS/MS daughter ions [m/z]
MTX 15.01 445 384 ? 358
1 13.74 750 621 ? 477
2 14.10 1,055 845 ? 775
3 15.61 503 442 ? 416
4 17.86 455 –
5 18.28 443 382 ? 356
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Fig. 3 LC/DAD-ESI/MS
chromatograms of (a) liver and
(b) heart extracts of MTX-
treated rats. Male Wistar rats
received 7.5 mg/kg MTX, via
intraperitoneal, and they were
euthanized 24-h after treatment.
The livers and hearts extracts
were obtained as described in
the ‘‘Materials and methods’’
section
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MTX cytotoxicity is prevented by the co-incubation
of MTX with CYP450 and CYP2E1 inhibitors
Trying to counteract the cytotoxicity of MTX, the effects
of CYP450 inhibitor MTP (0.5 mM) and CYP2E1 inhibitor
DAS (150 lM) were evaluated through the MTT reduction
assay. MTX (100 nM and 1 lM) was co-incubated with
MTP or DAS at 37 C for 96-h. Data are presented in
Fig. 5.
In the presence of MTP, the cytotoxic effects observed
after MTX incubation were significantly reduced compared
to those observed with MTX alone: the % of MTT
reduction was 69 ± 5 % for the MTX (100 nM) group
versus 81 ± 5 % for the MTX (100 nM) ? MTP
(0.5 mM) group and 63 ± 7 % for the MTX (1 lM) group
versus 74 ± 1 % for the MTX (1 lM) ? MTP (0.5 mM)
group (Fig. 5a). The incubation with MTP alone or the
DMSO 0.1 % group did not produce any measurable toxic
effect (99 ± 5 % and 95 ± 2 %, respectively) compared to
control (100 ± 4 %).
A partial reversion of the cytotoxicity of MTX using the
CYP2E1 subtype inhibitor DAS (150 lM) was also
observed. The co-incubation of MTX (100 nM) ? DAS
(150 lM) caused less toxic effects (73 ± 5 %) compared
to MTX (100 nM) alone (64 ± 4 %). The same was
observed in the MTX (1 lM) ? DAS (150 lM) (71 ± 4)
versus MTX 1 lM group (59 ± 8). The % reduction in
MTT in the DAS (150 lM) group (101 ± 4 %) was sim-
ilar to those observed in the control group (100 ± 6 %)
(Fig. 5b).
Discussion
The major findings of the present work are as follows:
(a) the description of the metabolic profile of MTX after
incubation with the rat hepatic S9 fraction; (b) the finding
that MTX and the naphtoquinoxaline metabolite are pres-
ent in the extracts of hearts and livers of male Wistar rats
treated with MTX 24-h before; (c) the demonstration of the
increase in the MTX cytotoxicity in the presence of its
metabolites toward H9c2 cells; and (d) the partial
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prevention of the MTX cytotoxicity with the inhibition of
the CYP450 and CYP2E1 metabolism in the H9c2 cells.
To the best of our knowledge, this is the first time that
the metabolism of MTX through the supplemented rat
hepatic S9 fraction is presented. Using this approach, 5
MTX metabolites were identified that keep the chromo-
phore group (Fig. 2), including the naphtoquinoxaline
metabolite (metabolite 5) and a novel metabolite that was
never described before (an acetoxy ester deriva-
tive, metabolite 3) (Table 1). The maintenance of the
chromophore group suggests that all these metabolites
possibly maintain the ability to intercalate into DNA base
pairs since the tricyclic planar structure is essential for
MTX activity (Hsin et al. 2008).
In order to overpass the described difficulty to stimulate
MTX metabolism in vitro (Duthie and Grant 1989; Richard
et al. 1991; Kostrzewa-Nowak et al. 2007) animals
received, as already reported, 0.2 % phenobarbital in
drinking water for 1 week prior to the S9 fraction isolation
to induce its metabolic systems (Wolf et al. 1986; Novak
and Kharasch 1985). The liver S9 fractions are considered
one of the most representative sub-cellular metabolic
in vitro systems because these fractions contain phase I and
phase II enzymes (Jia and Liu 2007; Yoshihara et al. 2001;
Brandon et al. 2003) and are much more illustrative of a
real situation than studies using exogenously and purified
added enzymes (Jia and Liu 2007; Brandon et al. 2003).
Subsequent analysis of S9 obtained extracts through LC/
DAD-ESI/MS presented in this work allowed an accurate
separation and identification of the metabolic profile of
MTX (Fig. 1; Table 1).
Studies discuss whether MTX suffers one-electron
reduction or two-electron reduction (Wolf et al. 1986;
Butler and Hoey 1987; Duthie and Grant 1989; Fisher and
Patterson 1992). In fact, the reduction in MTX by flavin
reductases is not facilitated due to its low one-electron
reduction potential (Fisher and Patterson 1992). Hence, the
preferential pathway of MTX metabolism is the two-elec-
tron reduction as evidenced by the prevention of the MTX
bioactivation with the inhibition of cytochrome P450-
mediated metabolism (Li et al. 1995; Duthie and Grant
1989; Mewes et al. 1993) that was also observed in this
work (Fig. 5).
The interest in the study of the metabolism of MTX has
emerged due to the discover that the naphtoquinoxaline
metabolite, which herein we called metabolite 5 (Table 1),
is involved in the anti-tumoral effect of MTX (Feofanov
et al. 1997; Mewes et al. 1993; Panousis et al. 1997). The
metabolite 5 was already described as the product of MTX
metabolism through heme containing enzymes systems,
CYP450, and peroxidases (Bru¨ck and Bru¨ck 2011; Blanz
et al. 1991). Other studies suggest that this metabolite
certainly has a significant role in the pharmacological
activity of MTX (Panousis et al. 1997; Feofanov et al.
1997; Mewes et al. 1993; Shipp et al. 1993) and may be
associated with MTX-induced adverse effects since it
causes ATP depletion in neonatal cardiomyocytes isolated
from rats (Shipp et al. 1993).
The conjugation with GSH, resulting in the metabolites 1
and 2 (Table 1), is the main detoxifying pathway of the
MTX (Mewes et al. 1993). These metabolites were previ-
ously found in studies with rat hepatic microsomes or
cytosol incubated with 1 mM MTX (Wolf et al. 1986) and
after incubation of 60 lg/mL MTX with horseradish per-
oxidase supplemented with 25 mg GSH (Blanz et al. 1991).
To the best of our knowledge, the metabolite 3 (Table 1)
was never associated with the MTX metabolism, although it
is important to refer that it is the first time that a complex
enzymatic system coupled to LC/DAD-ESI/MS analysis of
MTX metabolites is presented. We suggest that the acetoxy
derivative can result from an N-oxygenation in the aromatic
amine, followed by an acetylation. In fact, in primary and
secondary aromatic amines, N-oxygenation by cytochrome
P450 usually results in the formation of arylhydroxylam-
ines, which can be converted by N-acetyltransferases
(present in S9 fraction), functioning as O-acetyltransfer-
ases, to acetoxy esters (Parkinson and Ogilvie 2008).
As already stated, in our work, the metabolite 4 is
present only in trace amounts (Fig. 1). Thus, it was not
possible to obtain the complete MS fragmentation pattern.
However, the MS parent-ion mass of this compound is set
at m/z 455. Recently, a study with horseradish, lacto, and
lignin peroxidases incubated with MTX demonstrated the
presence of a metabolite with the same parental ion of
metabolite 4 (Bru¨ck and Bru¨ck 2011). Thus, based on this
study, it was suggested that the metabolite 4 could have the
proposed structure found on Table 1, the monocarboxylic
acid derivative. Mono and dicarboxylic acid MTX deriv-
atives were already associated with rat metabolism in very
low and variable levels (Blanz et al. 1991; Richard et al.
1991), which is in accordance with the trace amounts found
in our experiment with rat liver S9 fraction. In contrast,
they are considered the main metabolites of MTX in rabbits
and humans (Blanz et al. 1991; Richard et al. 1991),
highlighting the interspecies differences in the metabolic
profile of MTX.
An in vivo study was also performed to demonstrate the
metabolic profile of MTX and determine the metabolites in
the rat liver and heart (Fig. 3). The presence of MTX and
the metabolite 5 in both organs was shown. Despite this
metabolite has been already described in the urine of
humans and many laboratory animals (Blanz et al. 1991),
to the best of our knowledge, it is the first time that the
presence of the naphtoquinoxaline metabolite is described
in these organs in an in vivo situation. Furthermore, in liver
extracts, 7 additional metabolites were found that preserve
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the chromophore group. It is known that MTX is rapidly
and extensively distributed in tissues (An and Morris
2010), accumulating in organs such as liver and heart
(Ehninger et al. 1990). In humans, MTX was detected
35 days after a single dose of 12 mg/m2 in liver (1,140 ng/
g wet weight) and heart (716 ng/g wet weight) (Batra et al.
1986). The results presented here suggest that, as it hap-
pens with MTX, the naphtoquinoxaline metabolite also
accumulates in hepatic and cardiac tissue.
In the second part of this work, the effects of the MTX
bioactivation in a cardiomyoblast cellular in vitro model
were studied. The cellular damage assessed through the
MTT reduction assay was evaluated after 24-h incubation
with the extracts of previous incubation of supplemented
hepatic S9 fraction with 100 lM MTX at time 0 or 4-h
(containing about 35 % less MTX than at time 0 and the
metabolites presented in the Fig. 1; Table 1). As it can be
seen in the Fig. 4, even with less amounts of MTX, the
presence of the metabolites significantly increased the
cytotoxicity when compared to the non-metabolized MTX
group. A complex metabolic extract containing 5 in vitro
obtained metabolites (including the metabolite 5) was used,
and the results presented herein suggest the relevance
of MTX metabolism for cardiac damage. The unique study
correlating the bioactivation of MTX with its cardiotoxicity
is in agreement with our results since it shows that the
incubation of the previously synthesized and purified cyclic
metabolite (39 lM) (here named as metabolite 5, Table 1)
in neonatal cardiomyocytes isolated from rats caused a
partial depletion of the ATP content (Shipp et al. 1993).
Thus, it seems that the bioactivation of MTX can be
involved in both antitumoral and cardiotoxic effects. How-
ever, the mechanisms of pharmacological and adverse
effects of MTX may differ since it was already demonstrated
that the iron chelator ICRF-7 elicits cardioprotective effects
in isolated neonatal rat cardiomyocytes and prevents the
high-dose MTX lethality on CD-1 mice without counter-
acting the antitumor effect in two different tumor cell lines
and in an in vivo model of leukemia (Shipp et al. 1993).
This is the first time that the prevention of MTX-induced
cytotoxic effects by co-incubation with CYP450 metabo-
lism inhibitors is evidenced in a cardiomyoblast model. As
shown in the Fig. 5, the inhibition of CYP450-mediated
metabolism significantly decreased the cytotoxicity
observed with the same concentration of MTX in the
absence of the broad CYP inhibitor MTP, highlighting that
the in situ metabolism of MTX may also contribute to its
toxicity. Another major finding of this work is that, for the
first time, it is shown that similar protective results are
obtained with the co-incubation with DAS, a CYP2E1
subtype inhibitor (Fig. 5b). The heart is an organ
expressing both cytochrome P450 enzymes and NADPH
cytochrome reductase (Duthie and Grant 1989; Yoshihara
et al. 2001). CYP2E1 is markedly abundant in heart, and
we showed here that it contributes to MTX cytotoxicity.
The partial protection evidenced by the CYP inhibitors
may be related to the direct toxic effect of MTX or the
involvement of other enzymes present in the H9c2 cells
that can promote the bioactivation of MTX. There are
studies showing that the use of MTP prevents the cyto-
toxicity of MTX, namely in MCF7 human breast cancer
cells (Li et al. 1995), in human hepatoma-derived cells
(Duthie and Grant 1989; Mewes et al. 1993), and rat
hepatocytes (Mewes et al. 1993). Moreover, it was
observed a proportional relationship between the cellular
metabolic competences and the sensibility to MTX cellular
damage, since rat hepatocytes are more susceptible to the
cytotoxicity than hepatoma-derived cells (Mewes et al.
1993).
In summary, we presented the metabolic profile of MTX
after incubation with rat hepatic S9 fraction. Five poten-
tially MTX metabolites were presented, including the
metabolite 3 that was never described before and the
naphtoquinoxaline metabolite (metabolite 5). The metab-
olite 5 is considered the main bioactive product of MTX
metabolism (Mewes et al. 1993; Panousis et al. 1997). We
showed for the first time that this metabolite can be found
in rat liver and heart, prolonging the exposure period of
cardiac and hepatic cells to this bioactive compound. As
demonstrated in vitro, the presence of MTX metabolites
enhances the toxicity in a cardiomyoblast model. Further-
more, it was proved that the bioactivation of MTX medi-
ated through CYP450 and namely CYP2E1 metabolism
that occurs in loco in the cardiomyoblasts exerts a signif-
icant role in the cellular damage promoted by MTX. Thus,
these results suggest that besides the relevance of MTX
metabolism to its pharmacological action, the biotransfor-
mation fate of MTX might also be involved in its
cardiotoxicity.
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